Twist Bioscience Corporation
TWST
Positions held
Your positionsTWST isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Twist Bioscience operates in a rapidly growing biotechnology sector, focusing on synthetic DNA production, which is essential for various applications including pharmaceuticals and agriculture.
- Revenue increased by 7% compared to the prior quarter, reaching $118 million.
- Gross margin improved to 52.8%, up from 51.6% in the previous quarter.
- The company is facing significant financial challenges, with a negative profit margin of -31.66% and ongoing operating losses.
- Net income for the most recent quarter was -$35.051 million, indicating continued financial strain.
- The operating margin remains negative at -30.6%, reflecting ongoing operational inefficiencies.
Fundamentals
| Market cap | $10.08B | Enterprise value | $9.48B | Trailing P/E | — | Forward P/E | -380.13 |
| PEG | — | Price / book | 21.38 | Beta | 2.19 | Dividend yield | 0.00% |
| Revenue growth | 23.2% | Earnings growth | — | Gross margin | 52.0% | Operating margin | -30.6% |
| Profit margin | -31.7% | ROE | -29.6% | ROA | -13.1% | Debt / equity | 0.24 |
| Current ratio | 2.67 | Free cash flow | -$64.82M | Analyst recommendation | buy | Mean target | $150.33 |
| 52w high | $219.71 | 52w low | $23.30 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $118M | $111M | $104M | $99.0M | $96.1M | — |
| Op margin | -30.6% | -34.9% | -31.9% | -30.2% | -31.4% | — |
| Net income | -$35.1M | -$44.0M | -$30.5M | -$27.1M | $20.4M | — |
| Gross margin | 52.8% | 51.6% | 52.0% | 51.3% | 53.4% | — |
| Gross profit | $62.5M | $57.1M | $54.0M | $50.8M | $51.3M | — |
| Operating income | -$36.3M | -$38.7M | -$33.1M | -$29.9M | -$30.1M | — |
- Revenue +7% vs prior quarter ($118M vs $111M).
- Gross margin 52.8% (was 51.6% prior quarter).
- Operating margin expanded to -30.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $377M | $313M | $245M | $204M |
| Op margin | -36.2% | -56.2% | -84.4% | -122.3% |
| Net income | -$77.7M | -$209M | -$205M | -$218M |
| Gross margin | 50.7% | 42.6% | 36.6% | 41.4% |
| Gross profit | $191M | $133M | $89.7M | $84.2M |
| Operating income | -$136M | -$176M | -$207M | -$249M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Jefferies Initiates Twist Bioscience at Hold With $150 Price Target
2026-10-06 · NeoGenomics Sinks 12% on CEO Succession Plan Despite Revenue Beat
2026-10-06 · Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares
2026-10-05 · Cathie Wood’s ARKG Is Crushing Her Other ETFs: 2 Biotech Bets Have Surged Nearly 6X This Year
2026-10-02 · Twist Bioscience (TWST) Stock Fair Value Edges Higher As Analysts Split On AI Upside
2026-10-02 · Twist Bioscience (TWST) Stock Could Be Reasonable On Its 9x Three Year Run
2026-10-01 · AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment
2026-09-26 · Foundayo’s Early Growth Is Raising Lilly (LLY)’s Revenue Expectations. But Can It Outrun Pricing Pressure?
2026-09-25 · What Needs To Be True To Buy Twist Bioscience Stock Now?
2026-09-25 · Twist Bioscience Insider Sold Shares Worth $922,907, According to a Recent SEC Filing
2026-09-25 · Twist Bioscience Stock Jumped 16% Thursday. Leerink Says Anthropic Made It Happen.
2026-09-22 · Twist Bioscience (TWST) Expands AI Drug Discovery Exposure With Lilly TuneLab Partnership
Price (daily)
Full chart · RSI · MACD · patterns